Results 21 to 30 of about 3,394,140 (306)

Ferroptosis in cancer and cancer immunotherapy [PDF]

Cancer Communications, 2022
Abstract The hallmark of tumorigenesis is the successful circumvention of cell death regulation for achieving unlimited replication and immortality. Ferroptosis is a newly identified type of cell death dependent on lipid peroxidation which differs from classical programmed cell death in terms of morphology, physiology and biochemistry.
Lei Zhao, Xiaoxue Zhou, Feng Xie, Lei Zhang, Haiyan Yan, Jun Huang, Chong Zhang, Fangfang Zhou, Jun Chen, Long Zhang   +9 more
openaire   +3 more sources

High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study

Frontiers in Immunology, 2022
Background and ObjectiveThe results of the CheckMate 025 trial established the status of nivolumab in the second-line treatment of metastatic renal cell carcinoma (mRCC), with an objective response rate (ORR) of 25% and a complete response (CR) rate of 1%
Lingdi Zhao, Tiepeng Li, Yongping Song, Yonghao Yang, Baozhen Ma, Yong Zhang, Yiman Shang, Benling Xu, Jindong Guo, Peng Qin, Lu Han, Xiaomin Fu, Hongwei Lin, Liang Liu, Xiubao Ren, Zibing Wang, Quanli Gao   +16 more
doaj   +1 more source

Recent Advances and Challenges in Cancer Immunotherapy

, 2022
SIMPLE SUMMARY: Immunotherapy helps a person’s immune system to target tumor cells. Recent advances in cancer immunotherapy, including immune checkpoint inhibition, chimeric antigen receptor T-cell therapy and cancer vaccination, have changed the ...
Yiping Yang, Peterson, Chelsea, Denlinger, Nathan, Chelsea Peterson, Nathan Denlinger, Yang, Yiping   +5 more
core   +1 more source

Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again

Genome Medicine, 2018
For at least 300 years the immune system has been targeted to improve human health. Decades of work advancing immunotherapies against infection and autoimmunity paved the way for the current explosion in cancer immunotherapies.
Samantha L. Bucktrout, Jeffrey A. Bluestone, Fred Ramsdell   +2 more
doaj   +1 more source

Regulation of cell death in cancer - possible implications for immunotherapy [PDF]

, 2013
Since most anticancer therapies including immunotherapy trigger programmed cell death in cancer cells, defective cell death programs can lead to treatment resistance and tumor immune escape.
Simone Fulda, Simone eFulda, Fulda, Simone   +2 more
core   +1 more source

Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer

Scientific Reports, 2021
Despite recent progress in therapeutic strategies, prognosis of metastatic triple-negative breast cancer (TNBC) remains dismal. Evidence suggests that the induction and activation of tumor-residing conventional type-1 dendritic cells (cDC1s) is critical ...
Toshihiro Yokoi, Takaaki Oba, Ryutaro Kajihara, Scott I. Abrams, Fumito Ito   +4 more
doaj   +1 more source

ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism

OncoImmunology, 2017
Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components.
Alina Steinbach, Jan Winter, Miriam Reuschenbach, Renata Blatnik, Alexandra Klevenz, Miriam Bertrand, Stephanie Hoppe, Magnus von Knebel Doeberitz, Agnieszka K. Grabowska, Angelika B. Riemer   +9 more
doaj   +1 more source

The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy [PDF]

, 2021
Cancer immunotherapy harnesses the immune system by targeting tumor cells that express antigens recognized by immune system cells, thus leading to tumor rejection.
Narges Baluch, Neda Ashayeri, Qorri, Bessi, Kumar, Sushil, Das, Bikul, Cheng, Hai-Ling Margaret, Manpreet Sambi, Szewczuk, Myron R., Sambi, Manpreet, Hai-Ling Margaret Cheng, Ashayeri, Neda, Bikul Das, Myron R. Szewczuk, Herman Yeger, Bessi Qorri, Sushil Kumar, Yeger, Herman, Baluch, Narges, Mokhtari, Reza Bayat, Reza Bayat Mokhtari   +19 more
core   +1 more source

Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model

OncoImmunology, 2019
Therapeutic vaccination as a treatment option for HPV-induced cancers is actively pursued because the two HPV proteins E6 and E7 represent ideal targets for immunotherapy, as they are non-self and expressed in all tumor stages.
Sebastian Kruse, Marleen Büchler, Philipp Uhl, Max Sauter, Philipp Scherer, Tammy C.T. Lan, Samantha Zottnick, Alexandra Klevenz, Ruwen Yang, Frank Rösl, Walter Mier, Angelika B. Riemer   +11 more
doaj   +1 more source

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma

Frontiers in Pharmacology, 2023
Introduction: This study aimed to identify immune mediators, including cytokines, chemokines, and growth factors, in the plasma for predicting treatment efficacy and immune-related adverse events (irAEs) in advanced urothelial carcinoma (aUC) treated ...
Yosuke Shibata, Takeshi Kishida, Taku Kouro, Taku Kouro, Feifei Wei, Feifei Wei, Yuka Igarashi, Yuka Igarashi, Hidetomo Himuro, Hidetomo Himuro, Takeaki Noguchi, Mitsuyuki Koizumi, Takahisa Suzuki, Kimito Osaka, Yusuke Saigusa, Tetsuro Sasada, Tetsuro Sasada   +16 more
doaj   +1 more source